The Neuroendocrine Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuroendocrine Tumor pipeline products will significantly revolutionize the Neuroendocrine Tumor market dynamics.
DelveInsight’s “Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Neuroendocrine Tumor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Neuroendocrine Tumor market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuroendocrine Tumor Market Forecast
Some of the key facts of the Neuroendocrine Tumor Market Report:
The Neuroendocrine Tumors market size is estimated to grow at a significant CAGR during the forecasted period (2020-2034)
In March 2025, Exelixis, Inc. (Nasdaq: EXEL) has announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for two new indications: 1) for adults and adolescents aged 12 and older with previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET); and 2) for the same age group with previously treated, unresectable, locally advanced or metastatic well-differentiated extra-pancreatic neuroendocrine tumors (epNET). Neuroendocrine tumors (NETs) are a diverse group of cancers originating from neuroendocrine cells in the digestive system and other organs, including the pancreas and lungs.
In February 2025, ITM Isotope Technologies Munich SE (ITM), a prominent radiopharmaceutical biotechnology firm, has revealed encouraging topline findings from its Phase III COMPETE study. This trial assessed ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiotherapy, in individuals with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The data showed that ITM-11 delivered a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to everolimus, a current standard treatment option.
In January 2025, Cabozantinib (Cabometyx) demonstrated a significant improvement in progression-free survival (PFS) compared to placebo in patients with extrapancreatic neuroendocrine tumors (NETs) originating from the gastrointestinal (GI) tract who had received prior treatment. Findings from the Phase 3 CABINET trial (NCT03375320), shared at the 2025 Gastrointestinal Cancers Symposium, revealed that the PFS advantage was consistent across various clinical subgroups—except in patients with non-midgut GI primary tumors.
The total market size for NETs in the US was estimated at approximately USD 1,530 million in 2023 and is projected to experience significant growth with a strong CAGR throughout the forecast period.
In 2023, the total number of new NET cases in the US was approximately 29,500, with projections indicating an increase over the forecast period.
Non-functional, asymptomatic, or unknown NETs represent the largest portion of NET cases by functional status. In 2023, the US saw approximately 16,000 new cases of non-functional/asymptomatic/unknown NETs, compared to around 15,000 new cases of functional NETs.
In 2023, the UK had the highest number of NET cases among the EU4 and the UK, accounting for approximately 30% of the total cases in this region.
Around 35–37% of patients were diagnosed with low-grade neuroendocrine neoplasms, followed by 17–24% with intermediate-grade neoplasms. Only 6–7% of patients had high-grade disease, while the grade classification for the majority of patients remains unknown.Around 35–37% of patients were diagnosed with low-grade neuroendocrine neoplasms, followed by 17–24% with intermediate-grade neoplasms. Only 6–7% of patients had high-grade disease, while the grade classification for the majority of patients remains unknown.
Key Neuroendocrine Tumor Companies: Advanced Accelerator Applications (AAA)/Novartis, Ipsen Biopharmaceuticals, Novartis, Pfizer, Bausch Health and Ono Pharma, Merck, IITM Isotope Technologies Munich, Camurus, RayzeBio, Fundación de investigación HM, Radiomedix, Inc., Sinotau Pharmaceutical, Clarity Pharmaceuticals, ITM Solucin GmbH, Biotheus Inc., Aadi Bioscience, Inc., Novartis, TaiRx, Inc., Hutchmed, Perspective Therapeutics, Jiangsu HengRui Medicine, Nicholas Fidelman, MD, and others
Key Neuroendocrine Tumor Therapies: LUTATHERA (lutetium Lu 177 dotatate), SOMATULINE DEPOT (lanreotide), AFINITOR (everolimus), (sunitinib malate), DEMSER Capsule (metyrosine), WELIREG (belzutifan/MK-6482), ITM-11, CAM2029, RYZ101, 177Lu-Dotatate, AlphaMedix, Lutetium[177Lu], 64Cu-SARTATE, 177Lu-edotreotide PRRT, PM8002, nab-sirolimus, [68Ga]Ga-DOTA-TATE, CVM-1118, Surufatinib, [212Pb]VMT-α-NET, 68Ga-DOTATOC, Pembrolizumab, and others
Neuroendocrine Tumor Overview
Neuroendocrine tumors (NETs) are rare, abnormal growths that develop from neuroendocrine cells, which have both hormone-producing and nerve-like properties. These tumors can occur in various organs, most commonly in the lungs, gastrointestinal tract, and pancreas. NETs may produce excess hormones, leading to symptoms like flushing, diarrhea, or abdominal pain. They range from slow-growing (benign) to aggressive (malignant) forms. Diagnosis often involves imaging tests, biopsies, and blood tests. Treatment depends on the type, location, and stage, and may include surgery, medication, hormone therapy, or targeted therapies.
Get a Free sample for the Neuroendocrine Tumor Market Report:
https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market
Neuroendocrine Tumor Market
The dynamics of the Neuroendocrine Tumor market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Neuroendocrine Tumor Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Neuroendocrine Tumor Epidemiology Segmentation:
The Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Neuroendocrine Tumor
Prevalent Cases of Neuroendocrine Tumor by severity
Gender-specific Prevalence of Neuroendocrine Tumor
Diagnosed Cases of Episodic and Chronic Neuroendocrine Tumor
Download the report to understand which factors are driving Neuroendocrine Tumor epidemiology trends @ Neuroendocrine Tumor Epidemiological Insights
Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Neuroendocrine Tumor Therapies and Key Companies
LUTATHERA (lutetium Lu 177 dotatate): Advanced Accelerator Applications (AAA)/Novartis
SOMATULINE DEPOT (lanreotide): Ipsen Biopharmaceuticals
AFINITOR (everolimus): Novartis
SUTENT (sunitinib malate): Pfizer
DEMSER Capsule (metyrosine): Bausch Health and Ono Pharma
WELIREG (belzutifan/MK-6482): Merck
ITM-11: ITM Isotope Technologies Munich
CAM2029: Camurus
RYZ101: RayzeBio
177Lu-Dotatate: Fundación de investigación HM
AlphaMedix: Radiomedix, Inc.
Lutetium[177Lu]: Sinotau Pharmaceutical
64Cu-SARTATE: Clarity Pharmaceuticals
177Lu-edotreotide PRRT: ITM Solucin GmbH
PM8002: Biotheus Inc.
nab-sirolimus: Aadi Bioscience, Inc.
[68Ga]Ga-DOTA-TATE: Novartis
CVM-1118: TaiRx, Inc.
Surufatinib: Hutchmed
[212Pb]VMT-α-NET: Perspective Therapeutics
68Ga-DOTATOC: Jiangsu HengRui Medicine
RYZ101: RayzeBio, Inc.
Pembrolizumab: Nicholas Fidelman, MD
To know more about Neuroendocrine Tumor treatment, visit @ Neuroendocrine Tumor Medications
Neuroendocrine Tumor Market Strengths
NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes.
Treatment of NETs involves a multidisciplinary team of specialists, including oncologists, surgeons, and endocrinologists, which enhances the overall management of the disease
Neuroendocrine Tumor Market Opportunities
Continued research and development in targeted therapies, such as somatostatin analogs and molecular inhibitors, provide opportunities for more effective and personalized treatment approaches.
Participation in clinical trials can lead to the discovery of new treatment modalities and contribute to the improvement of patient outcomes.
Scope of the Neuroendocrine Tumor Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Neuroendocrine Tumor Companies: Advanced Accelerator Applications (AAA)/Novartis, Ipsen Biopharmaceuticals, Novartis, Pfizer, Bausch Health and Ono Pharma, Merck, ITM Isotope Technologies Munich, Camurus, RayzeBio, Fundación de investigación HM, Radiomedix, Inc., Sinotau Pharmaceutical, Clarity Pharmaceuticals, ITM Solucin GmbH, Biotheus Inc., Aadi Bioscience, Inc., Novartis, TaiRx, Inc., Hutchmed, Perspective Therapeutics, Jiangsu HengRui Medicine, Nicholas Fidelman, MD, and others
Neuroendocrine Tumor Therapeutic Assessment: Neuroendocrine Tumor current marketed and Neuroendocrine Tumor emerging therapies
Neuroendocrine Tumor Market Dynamics: Neuroendocrine Tumor market drivers and Neuroendocrine Tumor market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Neuroendocrine Tumor Market Access and Reimbursement
Discover more about therapies set to grab major Neuroendocrine Tumor market share @ Neuroendocrine Tumor Treatment Landscape
Table of Contents
1. Neuroendocrine Tumor Market Report Introduction
2. Executive Summary for Neuroendocrine Tumor
3. SWOT analysis of Neuroendocrine Tumor
4. Neuroendocrine Tumor Patient Share (%) Overview at a Glance
5. Neuroendocrine Tumor Market Overview at a Glance
6. Neuroendocrine Tumor Disease Background and Overview
7. Neuroendocrine Tumor Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuroendocrine Tumor
9. Neuroendocrine Tumor Current Treatment and Medical Practices
10. Neuroendocrine Tumor Unmet Needs
11. Neuroendocrine Tumor Emerging Therapies
12. Neuroendocrine Tumor Market Outlook
13. Country-Wise Neuroendocrine Tumor Market Analysis (2020–2034)
14. Neuroendocrine Tumor Market Access and Reimbursement of Therapies
15. Neuroendocrine Tumor Market Drivers
16. Neuroendocrine Tumor Market Barriers
17. Neuroendocrine Tumor Appendix
18. Neuroendocrine Tumor Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
